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Abstract
Gastrointestinal involvement in Langerhans cells histiocytosis (LCH) is extremely rare. 
An optimal treatment regimen is not defined yet and its prognosis is relatively poor. 
Cladribine, and more recently, Imatinib mesylate (IM) have been recommended as 
treatment options in refractory LCH. Here we present a case of gastrointestinal in-
volvement in an adult patient with LCH refractory to several treatment regimens who 
responded nicely to cladribine and currently treated with IM 300 mg/day, as mainte-
nance, for the last 24 months.
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Histiocitosis de células de Langerhans gastrointestinales con respuesta a cladribina 
y mesilato de imatinib
Resumen
Es muy raro que el aparato gastrointestinal sea afectado por la histiocitosis de células 
de Langerhans (HCL). No se ha definido todavía un régimen de tratamiento óptimo y su 
pronóstico es relativamente pobre. La cladribina, y más recientemente, el mesilato de 
imatinib (MI) se recomiendan como opciones de tratamiento en la HCL refractaria. Aquí 
presentamos un caso de un paciente adulto con HCL donde el aparato gastrointestinal 
está afectado y que era refractario a varios regímenes de tratamiento, pero respondió 
muy bien a la cladribina. Actualmente se le está tratando con 300 mg/dia de mesilato 
de imatinib, como dosis de mantenimiento durante los últimos 24 meses. 
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Background
Langerhans cell Histiocytosis (LCH) is a rare disease 
characterized by the neoplastic proliferation of Langer-
hans-type cells that express CD1a, langerin and S-100 
protein with variable number of eosinophils, neutrophils 
and small lymphocytes.1 Gastrointestinal involvement in 
LCH is rare and usually associated with severe systemic 
disease. An optimal treatment regimen that could lead to 
a lasting remission or cure is not defined yet but etoposide 
and vinblastine are considered to be the most effecti-
ve agents as monochemotherapy. Systemic treatments 
for refractory LCH have been unsatisfactory and usually 
toxic,2 however; Saven and Burian demonstrated that cla-
dribine has major activity in these patients.3 
On the other hand, imatinib mesylate (IM) is a 
competitive Bcr-Abl tyrosine kinase inhibitor showing ac-
tivity against the platelet-derived growth factor receptor 
(PDGF-R), c-Kit, Abl-related gene (ARG) and their fusion 
proteins while sparing other kinases. In vitro studies have 
demonstrated that exposure of CD34+ cells to imatinib 
mesylate affects the differentiation and functional pro-
perties of generated dendritic cells (DC). Furthermore, 
IM produces concentration-dependent reduced expres-
sion levels of CD1a, CD83, HLA-DR and CD40. This finding 
might be of major clinical importance because IM is given 
continuously so far to prevent disease relapse in LCH.4 
Recently, two patients suffering of both LCH and non-LCH 
improved with IM treatment.5, 6
Here we report the case of an adult patient with LCH 
who has improved considerably after treatment with cla-
dribine followed by IM as a maintenance drug.
Case report
A 37-year-old Hispanic woman presented to our institu-
tion in 2003 with chronic diarrhea and weight loss. Her 
symptoms began 10 years ago with epigastric burning 
pain, accompanied by gastroesophageal reflux as well 
as nausea and vomiting. A year later she continued with 
greenish stools decreased in consistency, with mucus, 
steatorrhea and lientheria related to food intake and ac-
companied by abdominal cramps, fever and weight loss. 
Her symptoms went into remissions and exacerbations 
during the follow-up. Later on, hyperpigmented maculae 
of 1 mm to 2 mm in diameter appeared in the back and 
abdomen, these dots were associated with exacerbation 
of the diarrhea. Whipple’s disease was initially diagno-
sed at another hospital but treatment was unsuccessful; 
therefore, she came to our hospital in 2003, due to per-
sistent symptoms and severe malnourishment. Neither 
adenopathy, liver or splenic enlargement were detected 
on physical examination. Endoscopic studies of both the 
upper and lower gastrointestinal tract revealed the pre-
sence of friable mucosa, a diffuse pattern of paved area, 
the presence of huge number of polyps and pseudopolyps 
ranging from stomach to the 2nd portion of the duodenum, 
terminal ileum, colon and rectum. Biopsies were taken 
and revealed and histiocytic infiltration (intermediate-
sized cells with irregular nuclei, vesicular chromatin, 
and indistinct nucleoili, with mitotic activity variable) of 
stomach, duodenum, ileum and colon which stained posi-
tive for CD68, CD1a and S-100 and negative for Whipple’s 
disease. Bone marrow biopsy showed infiltration by CD1a 
and S-100 positive cells too. These findings were consis-
tent with LCH. The skin biopsy was LCH negative. 
We diagnosed high-risk systemic LCH and chemothera-
py was initiated in December, 2003 on a weekly basis with 
vinblastine (6 mg/m2), etoposide (150 mg/m2) and daily 
prednisone (40 mg/m2) for five cycles without any impro-
vement. Therefore, in November, 2004 she was put on 
weekly methotrexate (12.5 mg/m2) and dexamethasone 
(40 mg), plus parenteral nutrition. The disease was sub-
sequently stable for 18 months and her clinical conditions 
Table 1. Clinical outcome according to therapeutic regimen.
Date Drugs Treatment duration Weight (Kg) Albumin (g/dL) GI endoscopy Biopsy
Dec-03
Vinblastine 
(6 mg/m2)
Etoposide 
(150 mg/m2)
Prednisone 
(40 mg/m2)
5 cycles 33.5 0.99
Polyps and 
pseudopolyps
Infiltrated by LCH
Nov-04 to Apr-06
Methotrexate 
(12.5 mg/m2)
Dexametasone 
(40 mg)
18 months 39.5 3.18
Polyps and 
pseudopolyps
Infiltrated
Jun-06 to May-07
Cladribine (5 mg/m2 
days 1 to 5)
8 cycles 55.3 4.0 Polyps Infiltrated
Oct-07
Imatinib mesylate 
(300 mg)
24 months and 
ongoing
57 4.0
Nodular pattern 
No polyps
Minimal infiltration 
by LCH
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partially improved. Nevertheless, during the treatment ta-
pering, symptoms reappeared while the upper and lower 
gastrointestinal tract as well as the bone marrow persis-
ted infiltrated. In June, 2006 she received cladribine (5 
mg/m2 days one to five) for eight cycles and there was an 
overall good clinical response (diarrhea disappeared), the 
endoscopy showed a nodular pattern in gastric mucosa 
with three polyps at the 2nd portion of duodenum and a 
large number or polyps in colon while the ileum and rectum 
showed a normal appearance; nevertheless the infiltra-
tion in both, the gastrointestinal tract and bone marrow 
persisted.
In October, 2007 we performed immunohistochemis-
try staining in gastrointestinal mucosal biopsy revealing 
CD117 positive in a pattern of membrane, (Figure 1) and 
PDGF-R positive with reinforcement in the cytoplasm 
membrane, so we decided to start Imatinib mesylate as 
maintenance therapy, initially at 400 mg P.O. daily but 
she developed a rash in upper extremities and diarrhea as 
adverse effects to IM, therefore, we reduced the IM dose 
to 300 mg/day. Currently, 24 months after initiating the 
IM maintenance therapy, she is in excellent clinical con-
ditions, without complaints. Moreover, the most recent 
endoscopic studies showed marked improvement of the 
GI lesions and was corroborated by the histopathologic 
reports, as shown in Table 1. However, infiltrate persists 
in the bone marrow.
Discussion
Neoplasms derived from Langerhans cells are clonal pro-
liferations, divided into two subgroups: Langerhans cell 
histiocytosis and Langerhans cell sarcoma, according to 
the degree of atypia and clinical aggressiveness. Some 
reactive cases, not clonal, have been observed in the lungs 
of smokers. LCH can affect a single site or multiple si-
tes in a single system or multisystem; it is characterized 
by cells measuring 10 μm to 15 μm, recognized by their 
Figure 1. Immunohistochemical stain. Duodenal biopsy shows Langerhans cells strongly reacting to CD117 and to PDGFR.
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grooved, folded, indented or lobulated nucleus with 
fine chromatin, inconspicuous nucleoli and thin nuclear 
membranes, with mitotic activity variable. The cyto-
plasm is moderately abundance and slightly eosinophilic. 
The ultrastructural hallmark is the cytoplasmic Birbeck 
granules, granules with a tennis racquet shape, and is 200 
nm to 400 nm long and 33 nm wide, with a zipper-like 
appearance. This cell expresses CD1a, langerin and s-100 
protein by immunohistochemistry stain.1
Gastrointestinal involvement in LCH is extremely rare 
and just few cases have been reported. Symptoms may 
include hematochezia, constipation or diarrhea and can 
range in severity from mild to life-threatening, whereas the 
diagnosis is made by endoscopic biopsy demonstrating 
the histological evidence of LCH. Even in patients without 
upper gastrointestinal tract symptoms, involvement by 
LCH is likely and should be treated as a multisystemic 
disease irrespective of the patient’s clinical status. Some 
researchers suggest that any gastrointestinal involvement 
in LCH warrants aggressive evaluation and treatment as 
the prognosis is relatively poor.2
Two recently informed cases suggest that treatment 
with IM could improve the course of patients with LCH 
and may be considered as an alternative treatment op-
tion for refractory LCH.5,6 Our current case illustrates 
that multisystemic LCH can be successfully treated with, 
at least two more drug choices: Cladribine and, in those 
patients with expression of KIT and/or PDGFR, IM.
However, we have to recognize that other resear-
chers have found inconsistent results in other forms of 
histiocytosis expressing PDGFR-β;7 therefore, large and 
multicenter studies should be considered to answer the 
question about the role of targeted therapy in this rare 
disease. 
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